Reviewing Progenics Pharmaceuticals Inc. (PGNX)’s and Arena Pharmaceuticals Inc. (NASDAQ:ARNA)’s results

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) and Arena Pharmaceuticals Inc. (NASDAQ:ARNA) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Progenics Pharmaceuticals Inc. 16.71M 20.69 72.97M -0.87 0.00
Arena Pharmaceuticals Inc. 817.27M 3.51 622.70M 12.15 4.61

We can see in table 1 the earnings per share, gross revenue and valuation of Progenics Pharmaceuticals Inc. and Arena Pharmaceuticals Inc.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Progenics Pharmaceuticals Inc. -436.68% -65.5% -35%
Arena Pharmaceuticals Inc. 76.19% -19.6% -17.1%

Risk and Volatility

Progenics Pharmaceuticals Inc. has a beta of 2.39 and its 139.00% more volatile than Standard and Poor’s 500. Arena Pharmaceuticals Inc.’s 1.68 beta is the reason why it is 68.00% more volatile than Standard and Poor’s 500.

Analyst Recommendations

The table shown features the ratings and recommendations for Progenics Pharmaceuticals Inc. and Arena Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Progenics Pharmaceuticals Inc. 0 0 2 3.00
Arena Pharmaceuticals Inc. 0 0 4 3.00

$11 is Progenics Pharmaceuticals Inc.’s consensus price target while its potential upside is 169.61%. On the other hand, Arena Pharmaceuticals Inc.’s potential upside is 9.84% and its consensus price target is $63.5. The data provided earlier shows that Progenics Pharmaceuticals Inc. appears more favorable than Arena Pharmaceuticals Inc., based on analyst opinion.

Insider & Institutional Ownership

Roughly 85.7% of Progenics Pharmaceuticals Inc. shares are owned by institutional investors while 86.5% of Arena Pharmaceuticals Inc. are owned by institutional investors. Insiders owned roughly 6.46% of Progenics Pharmaceuticals Inc.’s shares. Competitively, insiders own roughly 0.1% of Arena Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Progenics Pharmaceuticals Inc. -6.51% -4.87% 6.09% -9.8% -34.41% 16.19%
Arena Pharmaceuticals Inc. 13% 17.12% 15.5% 54.29% 22.67% 43.67%

For the past year Progenics Pharmaceuticals Inc. was less bullish than Arena Pharmaceuticals Inc.

Summary

Arena Pharmaceuticals Inc. beats Progenics Pharmaceuticals Inc. on 10 of the 12 factors.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The companyÂ’s proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.